Table 2. Time-dependent survival analysis (overall survival) stratified according to tumour type.

			Overall survival						Relative survival
	No. at risk	No. events	Crude hazard ratio	95% CI	P-value	Adjusted hazard ratioa	95% CI	P-value	Crude relative excess risk	95% CI	Adjusted relative excess riska	95% CI
Aspirin users vs nonusers (n=9286)
Nonusers	8278	4776	1 (Reference)			1 (Reference)
Aspirin Users	1008	362	0.57	0.48–0.69	<0.001	0.52	0.44–0.63	<0.001	0.41	0.30–0.56	0.44	0.33–0.58
Aspirin users vs nonusers per tumour type
Oesophageal cancer (n=946)
Nonusers	886	722	1 (Reference)			1 (Reference)
Aspirin Users	60	30	0.42	0.22–0.81	0.01	0.45	0.23–0.88	0.02	0.34	0.15–0.77	0.31	0.14–0.70
Gastric cancer (n=750)
Nonusers	700	555	1 (Reference)			1 (Reference)
Aspirin Users	50	30	0.75	0.41–1.36	0.34	0.87	0.47–1.61	0.66	0.50	0.19–1.29	0.70	0.29–1.70
Pancreatic cancer (n=692)
Nonusers	667	631	1 (Reference)			1 (Reference)
Aspirin users	25	21	1.06	0.58–1.93	0.84	0.81	0.44–1.48	0.49	1.03	0.56–1.89	0.77	0.42–1.41
Hepatobiliary cancer (n=385)
Nonusers	360	311	1 (Reference)			1 (Reference)
Aspirin Users	25	10	0.39	0.16–0.95	0.04	0.34	0.14–0.84	0.02	0.34	0.18–1.06	0.35	0.13–0.95
Colon cancer (n=3977)
Nonusers	3434	1587	1 (Reference)			1 (Reference)
Aspirin Users	543	178	0.62	0.48–0.80	<0.001	0.56	0.43–0.72	<0.001	0.41	0.23–0.72	0.44	0.27–0.72
Rectal cancer (n=2358)
Nonusers	2069	891	1 (Reference)			1 (Reference)
Aspirin Users	289	85	0.51	0.33–0.77	0.001	0.41	0.27–0.63	<0.001	0.26	0.09–0.78	0.25	0.09–0.68

Abbreviation: CI, confidence interval.

^aAdjusted for stage, sex, age at diagnosis, surgery, radiotherapy, chemotherapy and comorbidities.